GlucoTrack, Inc., was incorporated under the laws of the State of Delaware on May 18, 2010. The Company is a medical device company focused on the design, development and commercialization of new technologies for patients with diabetes and prediabetes. The company is currently developing two products: a non-invasive glucose monitor for patients with type 2 diabetes and prediabetes, and an implantable continuous glucose monitor for patients with type 1 diabetes and insulin-dependent type 2 diabetes. 

Glucotrack - Announces 1-for-15 reverse stock split effective August 31, 2026

GlucoTrack

Glucotrack - Announces 1-for-15 reverse stock split effective August 31, 2026

On August 7, 2026, Glucotrack, Inc. executed <a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315226033393/form8-k.htm">Amendment No. 1 to its</a> Stock Purchase Agreement with White Lion Capital, as disclosed in a recent SEC filing. The amendment outlines adjustments to the original terms of the agreement, though specific details of the modifications have not been publicly detailed in the filing. This development follows ongoing efforts by the company to secure capital and refine its financial structure.The filing, submitted through the SEC’s EDGAR database, is part of Glucotrack’s ongoing compliance with federal securities regulations. While the amendment does not indicate a change in the company’s broader strategic direction, it reflects the company’s engagement with investors and its commitment to transparency in corporate governance.Further details regarding the terms of the amendment and its potential impact on Glucotrack’s financial position will be available in subsequent filings or disclosures. Investors are advised to monitor official SEC submissions and company announcements for additional information.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1cf6335ebc3d4001.png" alt="Glucotrack - enters amendment No. 1 to stock purchase agreement with White Lion Capital on Aug 7th - SEC filing">

Glucotrack - enters amendment No. 1 to stock purchase agreement with White Lion Capital on Aug 7th - SEC filing

E.F. Hutton & Co. acted as exclusive financial advisor for Glucotrack's $5.5 million financing, led by institutional investors, with a $2.0 million equity financing and $3.5 million convertible debt investment. The transaction reflects investor confidence in the company's long-term strategy and provides additional capital to support its therapeutic platform. E.F. Hutton CEO Joseph T. Rallo commented on the success of the financing, citing the continued growth of the company.

E.F. Hutton advises Glucotrack on $5.5 mln financing.

Glucotrack has secured $5.5 million in financing, including a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment in convertible debt. The equity financing consists of units with one share of common stock and one five-year warrant with an exercise price of $1.50 per share.Glucotrack has announced the completion of a $5.5 million financing round, comprising $2.0 million in equity financing and $3.5 million in convertible debt. The equity component was priced at $0.75 per unit, with each unit including one share of common stock and one five-year warrant exercisable at $1.50 per share. This structure provides investors with potential upside through the warrant component while supporting the company’s immediate capital needs through the equity raise. The convertible debt portion of the financing adds flexibility to the company’s capital structure, allowing for future conversion under terms to be determined at the time of conversion. The financing is expected to support ongoing operations and development initiatives. Investors participating in the equity financing have demonstrated confidence in the company’s strategic direction and long-term potential. The terms of the convertible debt, including interest rates and conversion features, were not disclosed in the provided materials. The financing round reflects continued investor interest in the company’s business model and growth prospects.

Glucotrack Secures $5.5mln Financing, Priced at Premium to Market

Glucotrack, Inc. raised $5.5 million in financing from institutional investors, including a $2 million equity financing at $0.75 per unit and a $3.5 million follow-on investment in the form of convertible debt. The equity financing consists of units priced at $0.75 per unit, with each unit comprised of one share of common stock and one five-year warrant with an exercise price of $1.50 per share. The financing strengthens Glucotrack's balance sheet, provides additional growth capital, and reflects confidence in the company's long-term strategy.

GCTK News